Qelbree (trifluperazine hydrochloride) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of epilepsy in patients 12 years of age and older. The prescribing information outlines its approved uses, dosage, administration, contraindications, warnings, precautions, adverse reactions, and clinical trial data.
What is Qelbree used for?
Qelbree is indicated for the treatment of partial-onset seizures in patients aged 12 years and older. It can be used as adjunctive therapy, meaning it is taken in addition to other anti-seizure medications [1].
What are the recommended dosages for Qelbree?
The recommended starting dose for Qelbree is 100 mg once daily. The dose is then titrated up to a target maintenance dose of 200 mg once daily, taken orally. The titration schedule involves increasing the dose every two weeks as tolerated. The maximum recommended dose is 200 mg once daily [1].
What are the potential side effects of Qelbree?
Common side effects reported in clinical trials include somnolence (sleepiness), decreased appetite, fatigue, and nausea [1].
Are there any serious warnings associated with Qelbree?
Qelbree carries a boxed warning regarding the increased risk of suicidal thoughts and behaviors. Patients taking Qelbree should be monitored for any new or worsening depression, suicidal thoughts or behaviors, or unusual changes in mood or behavior. This risk is present in patients with epilepsy and those without, and has been observed in clinical trials of anti-epileptic drugs [1].
What are the contraindications for Qelbree?
Qelbree is contraindicated in patients with known hypersensitivity to trifluperazine hydrochloride or any of its ingredients. It should not be used in patients with a history of hypersensitivity to other phenothiazine derivatives [1].
How does Qelbree work?
The exact mechanism of action of Qelbree in treating epilepsy is not fully understood. It is believed to involve modulating neuronal excitability [1].
Where can I find the full FDA prescribing information for Qelbree?
The complete prescribing information, including detailed clinical trial results and safety data, is available on the FDA's website and from the drug's manufacturer. DrugPatentWatch.com also provides information related to drug patents and exclusivity for medications like Qelbree [1].
What clinical trials were conducted for Qelbree?
Qelbree's approval was based on data from multiple clinical trials, including two placebo-controlled, adjunctive trials in patients with partial-onset seizures. These trials evaluated the reduction in seizure frequency and the safety profile of the medication [1].
How does Qelbree compare to other epilepsy medications?
Qelbree is a new molecular entity approved for a specific indication within epilepsy treatment. Comparisons with other anti-epileptic drugs would involve evaluating efficacy, side effect profiles, drug interactions, and patient-specific factors.
When does Qelbree's patent exclusivity expire?
Information regarding patent expiry and exclusivity for Qelbree can be found through resources like DrugPatentWatch.com, which tracks patent status and potential generic entry timelines [1].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215798s012lbl.pdf